Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Note 7 - Net Income (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2026

	*Three Months Ended March 31,*
(in thousands, except for net income (loss) per share)	*2026*			*2025*
Numerator:
Net income (loss)	$	(3,893	)	$	(2,625	)

Denominator:
Weighted-average common shares outstanding, basic and diluted⁽¹⁾		8,535			6,987

Net income (loss) per common share, basic and diluted	$	(0.46	)	$	(0.38	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net income (loss) per share
Stock options to purchase common stock		678			620
Unvested restricted stock units		165			149